2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1049

Heart Rate Variability Testing with Autonomic Nervous System Optimization: Could It Change the Course of Spending for Rheumatoid Arthritis Patients in the U.S.? an Exploratory Minimal Model Analysis
Abstract Number: 1050

Prevalence and Predictors of Knee Replacement Overuse and Underuse in the US
Abstract Number: 1051

Telemedicine for Rheumatoid Arthritis in the Alaska Native Population
Abstract Number: 1052

Systematic Review of Modelling Approaches and Quality for the Cost Effectiveness of sequential Targeted Therapy in Patients with Rheumatoid Arthritis That Show an Inadequate Response to at Least One Tumor Necrosis Factor Alpha Inhibitor
Abstract Number: 1053

Impact of Step Therapy Protocols on North Carolina Rheumatologists’ Job Satisfaction and the Quality of Care Received By Their Patients with Rheumatoid Arthritis
Abstract Number: 1054

Healthcare Utilization Profiles in Rheumatoid Arthritis – a Cluster Analysis
Abstract Number: 1055

A Combination of Self-Reported Symptoms and ACPA Testing Can Identify Individuals with Previously Undiagnosed Inflammatory Arthritis in a Health-Fair Setting
Abstract Number: 1056

Evolution of Health Care Consumption in the Knee and Hip Osteoarthritis Long Term Assessment Cohort, a French Population Based Cohort of Symptomatic Knee and/or Hip OA Patients
Abstract Number: 1057

Budgetary Impact Analysis of Real-World Dosing Patterns in Matched Cohorts of Rheumatoid Arthritis Patients Treated with Infliximab or Golimumab Intravenous Anti-TNF Medications
Abstract Number: 1058

Variation in DMARD Therapy Following Methotrexate Failure for Newly-Identified Rheumatoid Arthritis in a National Veterans Health Administration Cohort
Abstract Number: 1059

Cost-Effectiveness of Tai Chi Versus Physical Therapy for Knee Osteoarthritis
Abstract Number: 1060

Assessing Interferon Regulatory Factor 5 (IRF5) Function in Human Primary Immune Cells with Cell-Penetrating Peptides
Abstract Number: 1061

Cardiac Endothelial Cell Transcriptome Analyses Support a Pathological Role of Metabolic and Inflammasome Genes in Anti-SSA/Ro-Associated Congenital Heart Block
Abstract Number: 1062

Ptpn22 Regulates Synovial Slam Family Receptor Expression during Toll-like Receptor-Driven Suppression of Inflammatory Arthritis
Abstract Number: 1063

Activation of Toll-like Receptor 2 in Human Synovium Explants Increase Tissue Turnover and Secretion of Interleukin-6

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].